Publications by authors named "Willemieke de Goffau-Nobel"
Article Synopsis
- Abnormalities in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) may present targets for precision medicine, as the study evaluates mutations and translocations in primary BCP-ALL cells alongside the effectiveness of JAK inhibitors.
- The researchers found that mutations predominantly appeared in poorer prognosis subtypes, and specific translocations were limited to certain cases; both Momelotinib and ruxolitinib showed cytotoxic effects, but their success was affected by other factors.
- Notably, JAK inhibitors led to resistance due to mutation in other survival pathways and increased JAK2 signaling after stopping treatment, indicating a need for better optimization before clinical use in pediatric BCP-ALL.
